» Articles » PMID: 7642691

The Use of the Calvert Formula to Determine the Optimal Carboplatin Dosage

Overview
Specialty Oncology
Date 1995 Jan 1
PMID 7642691
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Carboplatin is a chemotherapeutic agent frequently used in the treatment of various malignancies. The myelotoxicity and clinical efficacy of carboplatin correlate with the clearance of the drug, which is correlated to the glomerular filtration rate (GFR). Dosing of this agent based solely upon the patients body surface area is therefore not accurate enough; the GFR, and thus the clearance of carboplatin differ in each patient irrespective of the body area. Consequently, some patients undergo a higher systemic exposure, expressed as the area under the plasma concentration/time curve (AUC), than others when dosages of carboplatin are given on the basis of the body surface area. A high AUC correlates with increased toxicity, thus increasing the risks of the treatment, but in the case of a low AUC the therapeutical efficacy decreases. This indicates that an individual dosing strategy is warranted to obtain the optimal AUC. In this article, the development and application of a simple equation, known as the Calvert formula, are discussed. This formula can be used to calculate the carboplatin dose accurately in order to obtain a target AUC by using only the GFR. The formula is: dose (mg) = AUC (mg ml-1 min) x [GFR (ml/min) + 25 (ml/min)]. This formula has proven to be, in both retrospective and prospective studies, a reliable tool to calculate the optimal dose of carboplatin Future studies should determine the value of the creatinine clearance as a measure for the GFR.

Citing Articles

Capturing Chemotherapy and Radiotherapy Dose Among Breast Cancer Patients With the Utah All-Payer Claims Database Compared With Gold-Standard Abstraction.

Koric A, Chang C, Lloyd S, Dodson M, Deshmukh V, Newman M Cancer Med. 2024; 13(22):e70411.

PMID: 39548728 PMC: 11568241. DOI: 10.1002/cam4.70411.


Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia.

Shah R, Polen-De C, McGree M, Fought A, Kumar A Curr Oncol. 2023; 30(11):9501-9513.

PMID: 37999108 PMC: 10670337. DOI: 10.3390/curroncol30110688.


Survival Analysis and Clinical Outcomes between Paclitaxel and Carboplatin Versus Carboplatin and Gemcitabine in Patients with Advanced-stage Non-small-cell Lung Cancer: A Single-center Cohort Study.

Boonsong T, Usaha S, Nakwan N, Ruklerd T, Khongthong P, Chang A Asian Pac J Cancer Prev. 2022; 23(10):3371-3378.

PMID: 36308361 PMC: 9924342. DOI: 10.31557/APJCP.2022.23.10.3371.


Management of a rare ovarian carcinosarcoma: A case report and literature review.

Fu J Exp Ther Med. 2022; 24(3):583.

PMID: 35949347 PMC: 9353508. DOI: 10.3892/etm.2022.11520.


Acoustic feedback enables safe and reliable carboplatin delivery across the blood-brain barrier with a clinical focused ultrasound system and improves survival in a rat glioma model.

McDannold N, Zhang Y, Supko J, Power C, Sun T, Peng C Theranostics. 2019; 9(21):6284-6299.

PMID: 31534551 PMC: 6735504. DOI: 10.7150/thno.35892.


References
1.
Newell D, Eeles R, Gumbrell L, Boxall F, Horwich A, Calvert A . Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. Cancer Chemother Pharmacol. 1989; 23(6):367-72. DOI: 10.1007/BF00435838. View

2.
Krigel R, Palackdharry C, Padavic K, Haas N, Kilpatrick D, Langer C . Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer. J Clin Oncol. 1994; 12(6):1251-8. DOI: 10.1200/JCO.1994.12.6.1251. View

3.
Daugaard G, Rossing N, Rorth M . Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol. 1988; 21(2):163-7. DOI: 10.1007/BF00257365. View

4.
Groth S . Calculation of 51Cr-EDTA clearance in children from the activity in one plasma sample by transformation of the biexponential plasma time-activity curve into a monoexponential with identical integral area below the time-activity curve. Clin Physiol. 1984; 4(1):61-74. DOI: 10.1111/j.1475-097x.1984.tb00645.x. View

5.
Childs W, Nicholls E, Horwich A . The optimisation of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis. Ann Oncol. 1992; 3(4):291-6. DOI: 10.1093/oxfordjournals.annonc.a058182. View